No profile data available.
Replimune Group, Inc. (REPL) is a healthcare company in the additional cancer treatment drugs industry, based in Woburn, United States, with about 465 full-time employees.
It reported revenue of $0 for fiscal year 2026, and net income of -$313.94 million. In Q1 2027 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $1.26 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2026; market data as of October 9, 2026.
, a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer.
Replimune reported $0 in revenue for fiscal year 2026. In Q1 2027 revenue was $0.
$1.26 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Inhibrx Biosciences, Inc. (INBX), AnaptysBio, Inc. (ANAB), Tyra Biosciences, Inc. (TYRA), Oric Pharmaceuticals, Inc. (ORIC).